At present, considering the still inconclusive findings from human and experimental models, and lack of knowledge on the patient subgroups that might respond best, it appears unlikely that blockage of PCSK9 will develop into a widespread tool to treat NASH. Here, PCSK9 is linked to metabolic dysfunction-associated steatohepatitis.